Liminal BioSciences Inc. LMNL

Healthcare Biotechnology

Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed for trading on the Nasdaq Global Market.

NDAQ:LMNL - Post by User

Liminal BioSciences Inc.

Bullboard Posts

Comment by HighteawithIntrepidon Oct 18, 2017 3:29pm

198 Views

Post# 26827989

RE:RE:Impact of Ryplazmin Approval

The Doors "Been Down So Long (Alternate Version)".

The reality is this is the markets view of PL. A rights offering at 10 for 1 brings
in 100 million and solves our primary problem, we spend money we don’t have.
End of story.

Bullboard Posts

Changing Europe’s dependency on HREE from China